Biotechnology

Franklin Templeton's Grant Bowers has suggested some US biotechnology companies verge on looking like "value stocks" despite the fierce rally enjoyed by the sector over the past half-decade.

Managers pick their top alternative assets

The FTSE 100 has fallen 1.3% as geopolitical tensions and yesterday's tech sell-off put fresh pressure on UK stocks.

The biotechnology sector has boomed since the recession, providing substantial returns for investors in specialist funds exposed to this area.

Dotcom bubble 2.0?

Dr. Daniel Koller, head of management team, BB Biotech

Investors are showing increasing willingness to pay for R&D pipelines in biotech, explains AXA Framlington's Linden Thomson.

What’s gone wrong with global funds?

Is it worth accessing medical tech stocks via crowdfunding?

Healthcare will see ‘once-in-a-lifetime’ structural shift